TAF8: A Potential Drug Target and Biomarker for Proteinte Taube Nuss

Target Name: TAF8

NCBI ID: G129685

TAF8

TAF8: A Potential Drug Target and Biomarker for Proteinte Taube Nuss

Proteinte Taube Nuss (PTN) is a type of protein that is expressed in various tissues, including the brain, heart, and kidneys. It is a key regulator of cell growth, differentiation, and survival, and has been implicated in a number of diseases, including neurodegenerative disorders, cancer, and autoimmune diseases. The protein is composed of two main subunits, Taube and Nuss, which are held together by a disulfide bond.

Recent studies have identified TAF8 as a potential drug target and biomarker for a number of diseases. In this article, we will explore the biology of TAF8, its potential as a drug target, and its potential as a biomarker for disease.

The Biology of TAF8

TAF8 is a 16-kDa protein that is expressed in various tissues, including the brain, heart, and kidneys. It is highly conserved, with only one known isoform. TAF8 is composed of two main subunits, Taube and Nuss, which are held together by a disulfide bond. The Taube subunit consists of a variable region (Region A) and a constant region (Region B). The Nuss subunit is similar to the Taube subunit but has a different N-terminus.

TAF8 plays a key role in regulating cell growth, differentiation, and survival. It is involved in the regulation of cell proliferation, differentiation, and apoptosis, as well as in the regulation of tissue repair and regeneration. TAF8 has been shown to play a role in the development and progression of a number of diseases, including neurodegenerative disorders, cancer, and autoimmune diseases.

Potential as a Drug Target

TAF8 has been identified as a potential drug target due to its involvement in the regulation of cell growth and survival. Several studies have shown that TAF8 can be targeted by small molecules, including inhibitors of its activity as a kinase. These inhibitors have been shown to have a number of potential therapeutic benefits, including the treatment of neurodegenerative disorders and cancer.

In addition to its potential as a drug target, TAF8 has also been identified as a potential biomarker for a number of diseases. The Taube subunit of TAF8 is the target of several biomarkers that have been shown to be associated with the development and progression of various diseases, including neurodegenerative disorders, cancer, and autoimmune diseases.

Potential as a Biomarker

TAF8 has been shown to play a role in the regulation of inflammation, which is a key factor in the development and progression of many diseases. The Nuss subunit of TAF8 has been shown to be involved in the regulation of inflammation, and has been implicated in the development of autoimmune diseases.

In addition to its potential as a drug target, TAF8 has also been identified as a potential biomarker for a number of diseases. The Taube subunit of TAF8 is the target of several biomarkers that have been shown to be associated with the development and progression of various diseases, including neurodegenerative disorders, cancer, and autoimmune diseases.

Conclusion

TAF8 is a protein that has been shown to play a key role in the regulation of cell growth, differentiation, and survival. Its potential as a drug target and biomarker for a number of diseases makes it an attractive target for further research. Further studies are needed to fully understand the biology of TAF8 and its potential as a drug

Protein Name: TATA-box Binding Protein Associated Factor 8

Functions: The TFIID basal transcription factor complex plays a major role in the initiation of RNA polymerase II (Pol II)-dependent transcription (PubMed:33795473). TFIID recognizes and binds promoters with or without a TATA box via its subunit TBP, a TATA-box-binding protein, and promotes assembly of the pre-initiation complex (PIC) (PubMed:33795473). The TFIID complex consists of TBP and TBP-associated factors (TAFs), including TAF1, TAF2, TAF3, TAF4, TAF5, TAF6, TAF7, TAF8, TAF9, TAF10, TAF11, TAF12 and TAF13 (PubMed:33795473). The TFIID complex structure can be divided into 3 modules TFIID-A, TFIID-B, and TFIID-C (PubMed:33795473). TAF8 is involved in forming the TFIID-B module, together with TAF5 (PubMed:33795473). Mediates both basal and activator-dependent transcription (PubMed:14580349). Plays a role in the differentiation of preadipocyte fibroblasts to adipocytes, however, does not seem to play a role in differentiation of myoblasts (PubMed:14580349). Required for the integration of TAF10 in the TAF complex (PubMed:14580349). May be important for survival of cells of the inner cell mass which constitute the pluripotent cell population of the early embryo (By similarity)

The "TAF8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TAF8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets